Treatment of multiple sclerosis–related trigeminal neuralgia with onabotulinumtoxinA

The effectiveness of onabotulinumtoxinA (BTX‐A) has been established in primary trigeminal neuralgia (TN). However, to the best of our knowledge, the efficacy of BTX‐A in secondary TN has not yet been studied.

[1]  Steven J Scrivani,et al.  Trigeminal neuralgia. , 2022, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[2]  K. Bölcskei,et al.  Mechanisms of Botulinum Toxin Type A Action on Pain , 2019, Toxins.

[3]  T. Nurmikko,et al.  European Academy of Neurology guideline on trigeminal neuralgia , 2019, European journal of neurology.

[4]  Raj Kumar.  Therapeutic use of botulinum toxin in pain treatment , 2018, Neuronal signaling.

[5]  David H. Miller,et al.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.

[6]  E. Eskandar,et al.  Surgical Treatment of Trigeminal Neuralgia. , 2017, Neurosurgery clinics of North America.

[7]  G. Cruccu,et al.  Trigeminal neuralgia – diagnosis and treatment , 2017, Cephalalgia : an international journal of headache.

[8]  Haifeng Zhang,et al.  Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial , 2014, The Journal of Headache and Pain.

[9]  G. Cruccu,et al.  Natural history and outcome of 200 outpatients with classical trigeminal neuralgia treated with carbamazepine or oxcarbazepine in a tertiary centre for neuropathic pain , 2014, The Journal of Headache and Pain.

[10]  M. El-Tamawy,et al.  Botulinum toxin-type A: could it be an effective treatment option in intractable trigeminal neuralgia? , 2013, The Journal of Headache and Pain.

[11]  Hai-Feng Zhang,et al.  Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial , 2012, Cephalalgia : an international journal of headache.

[12]  C. Solaro,et al.  Management of pain in multiple sclerosis: a pharmacological approach , 2011, Nature Reviews Neurology.

[13]  L. Behavioral,et al.  Središnja Medicinska Knjižnica , 2022 .

[14]  H. Diener,et al.  OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial , 2010, Cephalalgia : an international journal of headache.

[15]  H. Diener,et al.  Impaired trigeminal nociceptive processing in patients with trigeminal neuralgia , 2007, Neurology.

[16]  K. Burchiel.  A New Classification for Facial Pain , 2003, Neurosurgery.

[17]  M. Arnold.  Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition , 2018, Cephalalgia : an international journal of headache.